^(131)I-组合单克隆抗体局部放射免疫导向治疗肝癌的临床观察

CLINICAL TRIALS OF PARTIAL RADIOIMMUNITY TARGETING THERAPY WITH ^(131)I MONOCLONAL ANTIBODY FOR HEPATOCELLULAR CARCINOMA (HCC)

探讨13 1 I标记组合单克隆抗体S10 2、T9、CL 3(Cocktail法)局部导向治疗肝癌的近期疗效、毒副反应。采用IODO GEN法标记13 1I McAb,B超引导下经皮穿刺肿瘤局部注射 ,治疗 116例中晚期原发性肝癌 ,用量每次 5 0～ 70mCi。结果显示 ,本治疗有效率 (CR +PR) 2 9 3%,总有效率(CR +PR +MR) 5 3 4 %,一年生存率 38 2 %,中位生存期 34 7周 ,中位疾病进展期 12周。表明13 1I标记组合单克隆抗体局部导向治疗原发性肝癌属于微创手术 ,经济、疗效确切、毒副反应小。

To explore the therapeutic effects and toxic side-effect of 131I-McAb (S102, T9, CL-3) in the treatment of hepatocellular carcinoma (HCC). 131I-McAb, which was labelled by IODO-GEN method, with 50-70mCi of 131I, was percutaneously injected into the tumor under B-ultrasonic guidance in 116 patients. The results showed that the effective rate (CR+PR) was 29.3% (34/116), the overall effective rate (CR+PR+MR) was 53.4% (62/116), the one-year survival rate was 38.2% (39/102), the mean survival time was 34.7 weeks, and the mean tumor developing phase was 12 weeks. The results suggested that the use of 131I-McAb in the treatment of HCC is a low toxic, effective and minimal invasive operation.